| 2026-10-06 | Danuglipron and orforglipron engage GLP-1R through materially different interfaces: an unbiased molecular dynamics study Oztekin A, Turker S. | bioRxiv preprint |
| 2026-09-20 | Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs Labate AM, Villari P, Cimino E, Giacomelli L, Oladeji OA, Agosti B. | Preprints.org preprint |
| 2025-12-10 | The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis Zhou J, Wang F, Li S. | Front Endocrinol (Lausanne) |
| 2025-08-26 | "Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024) Tolkacheva EV, Saliev AY, Salakhov TL, Balakin KV, Ivanov RA, Chernyshov VV. | Curr Med Chem |
| 2025-08-22 | Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS Jaiswal A, Biradar R, Deshmukh V, Deshpande R, Nandi S. | J Pharm Biomed Anal |
| 2025-07-24 | Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system Dailey KA, Schneider LN, Petreaca RC, Yoder RJ. | MicroPubl Biol |
| 2025-06-20 | Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study Buckeridge C, Cobain S, Bays HE, Matsuoka O, Fukushima Y, Halstead P, Tsamandouras N, Sherry N, Gorman DN, Saxena AR. | Diabetes Obes Metab |
| 2025-03-01 | Danuglipron Ameliorates Pressure Overload-Induced Cardiac Remodelling Through the AMPK Pathway Wang P, Guo Z, Kong CY, Ma YL, Wang MY, Zhang XR, Yang Z. | J Cell Mol Med |
| 2023-11-07 | Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis Fatima H, Rangwala HS, Mustafa MS, Shafique MA, Abbas SR, Rizwan A, Fadlalla Ahmed TK, Arshad A. | Diabetes Metab Syndr Obes |
| 2023-11-02 | Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes Fediuk DJ, Gorman DN, Stoddard SA, Zhang Y, Ogden AG, Winton JA, Saxena AR. | J Clin Pharmacol |
| 2023-10-16 | Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M. | Metabolism |
| 2023-06-13 | Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes Saxena AR, Frias JP, Gorman DN, Lopez RN, Andrawis N, Tsamandouras N, Birnbaum MJ. | Diabetes Obes Metab |
| 2023-05-01 | Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ. | JAMA Netw Open |
| 2022-12-19 | A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus Ono R, Furihata K, Ichikawa Y, Nakazuru Y, Bergman A, Gorman DN, Saxena AR. | Diabetes Obes Metab |
| 2021-06-14 | Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA, Kim AM. | Nat Med |
